DOCSLIB.ORG

Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software 1816 1990/826 THE DRUG TARIFF 1990 PURSUANT to section 99 of the Social Security Act 1964, the Minister of Health hereby gives the following direction. ANALYSIS I. Title and commencement 15. Disputes 2. Interpretation PART I PART III GENERAL RULES AFFECTING DIRECTION MISCELLANEOUS PROVISIONS 3. Scope of direction 16. Claims on Department 4. Standards I 7. Allergy treatment sets 5. Charges for requirements 18. Payment for non·disposable syringes and needles PART 11 19. Payment for plastic syringes RULES FOR PRICING 20. Period and quantity of supply for 6. Calculation of payments doctors' and midwives' prescriptions 7. Application of Pricing Schedules 21. Period and quantity of supply for 8. Computation of selling price prescriptions for oral contraceptives 9. Rounding calculations 22. Period and quantity of supply for 10. Minimum charges dentist's prescriptions 11. Adjustment of dose volumes of oral 23. Original packs, and certain antibiotics liquid requirements 24. Bulk supply orders 12. Water 25. Practitioner's supply orders 13. Payment for bulk supply orders 26. Wholesale supply orders 14. Payment for practitioners' supply 27. Revocations and savings orders Schedule DIRECTION 1. Tide and commencement-(I) This direction may be cited as the Drug Tariff 1990. (2) This direction shall come into force on the 1st day of December 1990. 2. Interpretation-(1) In this direction, unless the context otherwise requires,- "The Act" means the Social Security Act 1964: "Board" means an Area Health Board under the Area Health Boards Act 1983 or a Hospital Board under the Hospitals Act 1952: 1990/326 Drug Tariff 1990 1817 "Class B controlled drug" means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975: "Controlled drug" means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act): "Dentist" means a person registered as a dentist under the Dental Act 1988: "The Department" means the Department of Health: "Doctor' means a medical practitioner registered under the Medical Practitioners Act 1968: "Director-General" means the chief executive of the Department: "Family group" means either- (a) One person, and one or more children in respect of whom the family benefit- (i) Is being paid to that person; or (ii) Would be paid to that person under Part I of the Act if the Director-General of Social Welfare were satisfied that the child or children concerned were likely to remain in New Zealand; or (b) Two persons (being persons who are legally married to each other or are regarded as husband and wife under section 63 (b) of the Act), and one or more children in respect of whom the (arnily benefit- (i) Is being paid to one or other of those persons; or (ii) Would be paid to one or other of those persons under Part I of the Act if the Director-General of Social Welfare were satisfied that the child or children concerned were likely to remain in New Zealand: "GST" means goods and services tax under the Goods and Services Tax Act 1985: "Licensed hospital" means a place or institution that is- (a) A licensed hospital within the meaning of Part V of the Hospitals Act 1957; or (b) Recognised and approved as a hospital for the purposes of Part 11 of the Act: "Midwife" means a person whose name appears for the time being in that part of the Register of Nurses kept under section 16 of the Nurses Act 1977 relating to registered midwives: "Month" means a period of 30 consecutive days: "Outpatient", in relation to a requirement, means a rerson who, as part of treatment at a hospital under the contro of a Board, is prescribed the requirement for consumption or use in the person's home: "Payment" means payment by the Department in accordance with this direction: "Practitioner" means a person who is a doctor, a dentist, or a midwife: "Pricing Schedules" means the official schedules for prescription pricing issued by the Department from time to time for the purpose of determining the prices to be paid to contractors in respect of requirements supplied by them: "Proprietary preparation" means a requirement that is supplied by reference to a trade mark or trade name or by reference to the name of its manufacturer: 1818 Drug Tariff 1990 1990/326 "The regulations" means the Social Security (Pharmaceutical Benefits) Regulations 1965*: "Requirement" means a pharmaceutical requirement: "The Schedule", means the Schedule to this direction. (2) Except as provided in subclause (1) of this clause, expressions defined in section 88 of the Act or regulation 2 of the regulations have the meanings so defined. PART I GENERAL RULES AFFECTING DIRECTION 8. Scope of direction-(I) Subject to- (a) Subclause (2) of this clause; and (b) The conditions (if any) specified in the second column of Part 11 of the Schedule opposite the reference to it in the first column of that Part,- every medicine, drug, and material specified in the first column of Part 11 of the Schedule, and every preparation (having an inert base) of any of them, is hereby declared to be included in this direction and to be a requirement for its purposes. (2) Medicines, drugs, and materials of the following classes are not included in this direction and are not requirements: (a) Substances, or combinations of substances, ordered for any purpose other than- (i) Treatment of a patient's medical or dental condition; or (ii) Pregnancy tests; or (iii) The prevention of sexually transmitted disease; or (iv) Contraception: (b) Unless it is specified in Part 11 of the Schedule that they may be so packed, substances, and combinations of substances, packed under pressure in aerosol cans or other similar devices: (c) Electrode jellies: (d) Unless it is specified in Part 11 of the Schedule that they may be so packed, eye drops packed in single· dose units: (e) Insect repellants and similar preparations: (f) Unless it is specified in Part 11 of the Schedule that they may be in such a form, oral preparations in long. acting form: (g) Unless it is specified in Part 11 of the Schedule that they may be in such a form, substances or combinations of substances, in lozenge or similar form: (h) Machine·spread plasters: (i) Preparations prescribed as foods: (j) Unless they are deemed or declared to be requirements elsewhere in this direction, substances, combinations of substances, or articles, in the form of proprietary medicines or proprietary articles: (k) Shampoos (other than extemporaneously prepared medicated shampoos, or shampoos specified in Part 11 of the Schedule, intended for the treatment of a patient's medical condition): (I) Toilet preparations: (m) Tooth pastes and powders: (n) Lubricating jellies and catheter lubricants: (0) Sterile diluents for nebulising solutions: ·S.R. 1965/41 1990/326 Drug Tariff 1990 1819 (p) Unless it is specified in Part 11 of the Schedule that they may be in such a form, substances in a form intended to enable delivery by transdermal diffusion or osmosis or by the insertion of any solid object or substance into the eye cavity: (q) Unless it is specified in Part 11 of the Schedule that they may be in such a form, substances in a form intended for intravenous delivery (otherwise than by injection): (r) Unless it is specified in Part 11 of the Schedule that they may be so packed, substances packed in pre-Ioaded syringes known as Min­ IJets: (s) Unless they are specified in Part 11 of the Schedule otherwise than in combination with other ingredients, requirements prescribed as cough mixtures: (t) Unless they are specified in Part 11 of the Schedule, vitamin preparations in capsule form: (u) Unless it is specified in Part 11 of the Schedule that they may be prescribed for such use, substances prescribed for use as irrigating solutions_ 4. Standards-No claim by a contractor for payment in respect of the supply of requirements shall be allowed unless the requirements so supplied- (a) Comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or (b) In the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or (c) In the absence of the standards described in paragraphs (a) and (b) of this clause, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or (d) In the absence of the standards described in paragraphs (a) to (c) of this clause, are of a grade and quality not lower than those usually applicable to requirements intended to be used for medical purposes. 5. Charges for requirements-(l) Subject to subclauses (2) to (4) of this clause, if any requirements are supplied to a patient as pharmaceutical benefits, they shall be so supplied free of charge to the patient, except that, if the requirements are to be delivered to the patient elsewhere than at the pharmacy or other place of business of the contractor, a reasonable charge in accordance with regulation 14 (2) of the regulations may be made for their delivery. (2) A contractor may charge a customer with- (a) The price of any requirements that are supplied in excess of the maximum quantities specified in this direction: (b) The lesser of- (i) Any amount by which payment for it is required to be reduced under any of clauses 6, 18, and 19 of this direction; and (ii) The total payment due (or any part of it): (c) In the case of a preparation specifically ordered by a practitioner and supplied by the contractor, all or any part of the sum of- (i) Any amount by which the price the contractor paid for it exceeds 0.80 of its selling price; and (ii) Half of that amount,- 1820 Drug Tariff 1990 1990/326 together with any GST payable in respect of the amount charged under subparagraphs (i) and (ii) of this paragraph.
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    554 1993/115 THE DRUG TARIFF 1998 PURSUANT to section 99 of the Social Security Act 1964, the Minister of Health hereby gives the following direction. ANALYSIS PART V ABATEMENTS 15. Group 2 cardholders 1. Title and commencement 16. Certain other cardholders 2. Interpretation 17. Contraceptives 18. Requirements in excess of 20 PART I 19. Class B controlled drugs REQ.UIREMENTS 20. The Hokianga 3. Requirements generally 4. Certain requirements excluded 5. Standards PART VI PRIGING PART II 21. Application of Pricing Schedules PERIOD AND QUANTITY OF SUPPLY 22. Computation of selling price 6. Doctors' and midwives' prescriptions 23. Rounding calculations (other than oral contraceptives) 24. Minimum charges 7. Oral contraceptives 25. Water 8. Dentists' prescriptions 26. Payments for bulk supply orders 9. Original packs, and certain antibiotics 27. Payment for practitioners' supply orders PART III 28. Allergy treatment sets CHARGES 29. Disputes 10. Restriction on charges I!. Part charges 12. Other permitted charges PART VII MISCELLANEOUS PROVISIONS PART IV 30. Claims on Department CALCULATION OF PAYMENTS 31. Bulk supply orders 13. Requirements other than hypodermic 32. Practitioner's supply orders syringes and needles 33. Wholesale supply orders 14. Hypodermic syringes and non· 34. Revocations and savings disposable hypodermic needles Schedules 1993/115 Drug Tariff 1993 555 DIRECTION 1. Tide and commencement-(I) This direction may be cited as the Drug Tariff 1993. (2) This direction shall come into force on the 1st day of May 1993. 2. Interpretation-(I)
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • R&D UNICANCER Annual Report 2016
    Going further, innovating together R&D UNICANCER Annual Report 2016 Summary Presentation and organisation Regulatory affairs, pharmaco- PAGE 01 vigilance, quality assurance – Ensuring quality and safety 2016 clinical activity in clinical trials. PAGE 08 PAGE 25 Expert groups Epidemiological Strategy and PAGE 16 Medical Economics (ESME) 2016 publications Programme – Harnessing PAGE 21 real-life data in oncology to improve patient care. Clinical operations PAGE 27 PAGE 23 Development Biological Resource and partnerships – Centre (BRC) Optimising collaborations PAGE 24 to foster innovation PAGE 30 Research in the FCCC PAGE 32 Appendices PAGE 33 Contacts, Follow us PAGE 45 GOING FURTHER, INNOVATING TOGETHER R&D ANNUAL REPORT 2016 Presentation and organisation UNICANCER, a major French player in oncology, Acteur majeur de la cancérologie française, groups together 20 French Comprehensive Cancer UNICANCER regroupe les 20 Centres de lutte contre Centers (FCCC). They are private, non-profit health la cancérologie (CLCC), établissements de santé establishments exclusively dedicated to care, research privés à but non lucratif exclusivement dédiés aux and education in cancer. UNICANCER’s R&D soins, à la recherche et à l’enseignement en cancéro- department is the driving force of UNICANCER’s logie. R&D UNICANCER en tant que promoteur research and, as an academic sponsor, it works direc- aca démi que, travaille en direct avec les unités de tly with the research units of the FCCC and other recherche des CLCC et d’autres établissements health establishments (university hospitals, hospitals de santé (CHU, CH, cliniques) en France et à l’inter- and clinics) in France and abroad. The mission of R&D national.
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/009638 Al 11 January 2018 (11.01.2018) W !P O PCT (51) International Patent Classification: Published: C07D 413/14 (2006.01) A61K 31/553 (2006.01) — with international search report (Art. 21(3)) C07D 403/14 (2006.01) A61P 35/00 (2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/040866 amendments (Rule 48.2(h)) (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,001 06 July 2016 (06.07.2016) 62/454,163 03 February 2017 (03.02.2017) (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office Of Technology Tran s fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: ROSS, Brian, D.; 2410 Foxway, Ann Arbor, MI 48105 (US). VAN DORT, Marcian; 643 Dornoch Dr., Ann Arbor, MI 48103 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Rediscovery of Fexinidazole
    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter
    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]